Dyax Corp (NASDAQ:DYAX)

25.75
Delayed Data
As of Apr 01
 +9.00 / +53.69%
Today’s Change
6.05
Today|||52-Week Range
26.11
+83.14%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.3B

Company Description

Dyax Corp. is a biopharmaceutical company, which discovers, develops and commercializes biopharmaceuticals for unmet medical needs. The company utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. It also develops angioedema portfolio for the prophylactic treatment of hereditary angioedema and a diagnostic test to identify plasma kallikrein-mediated disorders. Dyax was founded in 1995 and is headquartered in Burlington, MA.

Contact Information

Dyax Corp.
55 Network Drive
Burlington Massachusetts 01803
P:(617) 225-2500
Investor Relations:
(617) 250-5741

Employees

Shareholders

Individual stakeholders7.91%
Mutual fund holders58.76%
Other institutional38.82%

Top Executives

Gustav A. ChristensenPresident, Chief Executive Officer & Director
George V. MigauskyChief Financial Officer & Executive Vice President
Burt A. AdelmanChief Medical Officer, EVP-Research & Development
Todd BazemoreChief Commercial Officer & Executive VP
Andrew D. AsheSenior Vice President & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account